120 related articles for article (PubMed ID: 8981299)
1. Effects of the calcium channel blockers Dotarizine and Flunarizine on cerebrovascular reactivity.
Czernicki Z; Jurkiewicz J; Bojanowski K; Piechnik S; Cervos-Navarro J
J Neurol Sci; 1996 Nov; 143(1-2):60-3. PubMed ID: 8981299
[TBL] [Abstract][Full Text] [Related]
2. Effect of dotarizine on CO2-dependent cerebrovascular reactivity.
Chomicki J; Jurkiewicz J; Zabolotny W; Czernicki Z; Cervos-Navarro J
Acta Neurochir (Wien); 1995; 136(3-4):186-8. PubMed ID: 8748852
[TBL] [Abstract][Full Text] [Related]
3. Regional differences of cerebrovascular reactivity effected by calcium channel blocker - dotarizine.
Kuridze N; Czernicki Z; Jarus-Dziedzic K; Jurkiewicz J; Cervos-Navarro J
J Neurol Sci; 2000 Apr; 175(1):13-6. PubMed ID: 10785251
[TBL] [Abstract][Full Text] [Related]
4. Vasostabilizing effect of Dotarizine (Ca(2+)-channel blocker) on cerebrovascular reactivity in rabbits.
Kuridze N; Czernicki Z; Jarus-Dziedzic K; Jurkiewicz J; Cervos-Navarro J
Neurol Res; 2000 Mar; 22(2):229-32. PubMed ID: 10763515
[TBL] [Abstract][Full Text] [Related]
5. Dotarizine versus flunarizine as calcium antagonists in chromaffin cells.
Villarroya M; Gandía L; Lara B; Albillos A; López MG; García AG
Br J Pharmacol; 1995 Jan; 114(2):369-76. PubMed ID: 7881736
[TBL] [Abstract][Full Text] [Related]
6. Effect of oral administration of dotarizine on cerebrovasculature subjected to constriction followed by dilatation in rabbits.
Jarus-Dziedzic K; Czernicki Z; Cervos-Navarro J; Jurkiewicz J
Acta Neurochir (Wien); 1999; 141(11):1209-12. PubMed ID: 10592122
[TBL] [Abstract][Full Text] [Related]
7. Effects of dotarizine and flunarizine on chromaffin cell viability and cytosolic Ca2+.
Novalbos J; Abad-Santos F; Zapater P; Cano-Abad MF; Moradiellos J; Sánchez-García P; García AG
Eur J Pharmacol; 1999 Feb; 366(2-3):309-17. PubMed ID: 10082213
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms of blockade by the novel migraine prophylactic agent, dotarizine, of various brain and peripheral vessel contractility.
Ruiz-Nuño A; Villarroya M; Cano-Abad M; Rosado A; Balfagón G; López MG; García AG
Eur J Pharmacol; 2001 Jan; 411(3):289-99. PubMed ID: 11164387
[TBL] [Abstract][Full Text] [Related]
9. Serotonergic effects of dotarizine in coronary artery and in oocytes expressing 5-HT2 receptors.
Montiel C; Herrero CJ; García-Palomero E; Renart J; García AG; Lomax RB
Eur J Pharmacol; 1997 Aug; 332(2):183-93. PubMed ID: 9286620
[TBL] [Abstract][Full Text] [Related]
10. The effect of Dotarizine (Ca2+ channel blocker) on cerebral vessel reactivity in animals subjected to hyperventilation and anoxia.
Czernicki Z; Kuridze N; Jurkiewicz J; Cervós-Navarro J
Acta Neurochir Suppl; 1997; 70():209-11. PubMed ID: 9416324
[TBL] [Abstract][Full Text] [Related]
11. Memory effects of the Ca2+ and 5-HT antagonists dotarizine and flunarizine.
Petkov VD; Konstantinova E; Petkov VV; Belcheva S; Kehayov R; Vaglenova J
Acta Physiol Pharmacol Bulg; 2000; 25(2):43-50. PubMed ID: 11140170
[TBL] [Abstract][Full Text] [Related]
12. Effects of Ca2+ channel blockers on cortical hypoperfusion and expression of c-Fos-like immunoreactivity after cortical spreading depression in rats.
Shimazawa M; Hara H; Watano T; Sukamoto T
Br J Pharmacol; 1995 Aug; 115(8):1359-68. PubMed ID: 8564192
[TBL] [Abstract][Full Text] [Related]
13. Behavioral changes as a result of dotarizine or flunarizine influence on dopaminergic neurotransmission in the striatum.
Petkov VD; Petkova B
Acta Physiol Pharmacol Bulg; 1998; 23(1):21-5. PubMed ID: 10347616
[TBL] [Abstract][Full Text] [Related]
14. The effect of Dotarizine--(Ca2+ channel blocker)--on vascular reactivity and ultrastructure of cerebral capillaries in animals subjected to anoxia.
Kuridze N; Gajkowska B; Czernicki Z; Jurkiewicz J; Cervos-Navarro J
Folia Neuropathol; 1998; 36(2):101-8. PubMed ID: 9757621
[TBL] [Abstract][Full Text] [Related]
15. Selective effects of lomerizine, a novel diphenylmethylpiperazine Ca2+ channel blocker, on cerebral blood flow in rats and dogs.
Hara H; Shimazawa M; Sasaoka M; Yamada C; Iwakura Y; Sakai T; Maeda Y; Yamaguchi T; Sukamoto T; Hashimoto M
Clin Exp Pharmacol Physiol; 1999 Nov; 26(11):870-6. PubMed ID: 10561807
[TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of the Ca2+/5-HT antagonist dotarizine.
Petkov VD; Belcheva S; Konstantinova E; Vaglenova J; Petkov VV
Acta Physiol Pharmacol Bulg; 1994; 20(1):9-17. PubMed ID: 7892769
[TBL] [Abstract][Full Text] [Related]
17. Cerebrovascular effects of dotarizine, a piperazine derivative, in the goat. An in vivo and in vitro complementary study.
Torregrosa G; Barberá MD; Ortí M; Centeno JM; Salom JB; Alborch E
Arzneimittelforschung; 1999 Aug; 49(8):668-72. PubMed ID: 10483512
[TBL] [Abstract][Full Text] [Related]
18. Novel antimigraineur dotarizine releases Ca2+ from caffeine-sensitive Ca2+ stores of chromaffin cells.
Novalbos J; Abad-Santos F; Zapater P; Alvarez J; Alonso MT; Montero M; García AG
Br J Pharmacol; 1999 Oct; 128(3):621-6. PubMed ID: 10516641
[TBL] [Abstract][Full Text] [Related]
19. [Changes in the blood circulation in the middle cerebral and common carotid arteries of rats under the influence of flunarizine].
Semkina GA; Matsievskiĭ DD; Mirzoian RS
Eksp Klin Farmakol; 1997; 60(1):28-31. PubMed ID: 9162277
[TBL] [Abstract][Full Text] [Related]
20. 'Wide-spectrum Ca2+ channel antagonists': lipophilicity, inhibition, and recovery of secretion in chromaffin cells.
Lara B; Gandía L; Torres A; Olivares R; Martínez-Sierra R; García AG; López MG
Eur J Pharmacol; 1997 Apr; 325(1):109-19. PubMed ID: 9151946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
